Antibody responses to Streptococcus Gallolyticus subspecies Gallolyticus proteins in a large prospective colorectal cancer cohort consortium

Julia Butt, William J. Blot, Lauren R. Teras, Kala Visvanathan, Loïc Le Marchand, Christopher A. Haiman, Yu Chen, Ying Bao, Howard D. Sesso, Sylvia Wassertheil-Smoller, Gloria Y. Ho, Lesley F. Tinker, Richard M. Peek, John D. Potter, Timothy L. Cover, Laura H. Hendrix, Li Ching Huang, Tim Waterboer, Michael Pawlita, Meira Epplein

Research output: Contribution to journalArticle

Abstract

Background: Antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG) proteins, especially pilus protein Gallo2178, have been consistently associated with colorectal cancer risk. Previous case-control studies and prospective studies with up to 8 years of follow-up, however, were unable to decipher the temporality of antibody responses to SGG in the context of the long-term multistep development of colorectal cancer. In this study, we analyzed a large U.S. colorectal cancer cohort consortium with follow-up beyond 10 years for antibody responses to SGG. Methods: We applied multiplex serology to measure antibody responses to 9 SGG proteins in participants of 10 prospective U.S. cohorts (CLUE, CPSII, HPFS, MEC, NHS, NYUWHS, PHS, PLCO, SCCS, and WHI) including 4,063 incident colorectal cancer cases and 4,063 matched controls. Conditional logistic regression was used to assess whether antibody responses to SGG were associated with colorectal cancer risk, overall and by time between blood draw and diagnosis. Results: Colorectal cancer risk was increased among those with antibody responses to Gallo2178, albeit not statistically significant [OR, 1.23; 95% confidence interval (CI), 0.99- 1.52]. This association was stronger for cases diagnosed <10 years after blood draw (OR, 1.40; 95% CI, 1.09-1.79), but was not found among cases diagnosed ≥10 years after blood draw (OR, 0.79; 95% CI, 0.50-1.24). Conclusions: In a large cohort consortium, we reproduced the association of antibody responses to SGG Gallo2178 with colorectal cancer risk for individuals diagnosed within 10 years after blood draw. Impact: This timing-specific finding suggests that antibody responses to SGG are associated with increased colorectal cancer risk only after tumorigenesis has begun.

Original languageEnglish (US)
Pages (from-to)1186-1194
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume27
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Antibody Formation
Colorectal Neoplasms
Proteins
Confidence Intervals
Streptococcus gallolyticus subspecies gallolyticus
Serology
Case-Control Studies
Carcinogenesis
Logistic Models
Prospective Studies

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Antibody responses to Streptococcus Gallolyticus subspecies Gallolyticus proteins in a large prospective colorectal cancer cohort consortium. / Butt, Julia; Blot, William J.; Teras, Lauren R.; Visvanathan, Kala; Le Marchand, Loïc; Haiman, Christopher A.; Chen, Yu; Bao, Ying; Sesso, Howard D.; Wassertheil-Smoller, Sylvia; Ho, Gloria Y.; Tinker, Lesley F.; Peek, Richard M.; Potter, John D.; Cover, Timothy L.; Hendrix, Laura H.; Huang, Li Ching; Waterboer, Tim; Pawlita, Michael; Epplein, Meira.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 27, No. 10, 01.10.2018, p. 1186-1194.

Research output: Contribution to journalArticle

Butt, J, Blot, WJ, Teras, LR, Visvanathan, K, Le Marchand, L, Haiman, CA, Chen, Y, Bao, Y, Sesso, HD, Wassertheil-Smoller, S, Ho, GY, Tinker, LF, Peek, RM, Potter, JD, Cover, TL, Hendrix, LH, Huang, LC, Waterboer, T, Pawlita, M & Epplein, M 2018, 'Antibody responses to Streptococcus Gallolyticus subspecies Gallolyticus proteins in a large prospective colorectal cancer cohort consortium', Cancer Epidemiology Biomarkers and Prevention, vol. 27, no. 10, pp. 1186-1194. https://doi.org/10.1158/1055-9965.EPI-18-0249
Butt, Julia ; Blot, William J. ; Teras, Lauren R. ; Visvanathan, Kala ; Le Marchand, Loïc ; Haiman, Christopher A. ; Chen, Yu ; Bao, Ying ; Sesso, Howard D. ; Wassertheil-Smoller, Sylvia ; Ho, Gloria Y. ; Tinker, Lesley F. ; Peek, Richard M. ; Potter, John D. ; Cover, Timothy L. ; Hendrix, Laura H. ; Huang, Li Ching ; Waterboer, Tim ; Pawlita, Michael ; Epplein, Meira. / Antibody responses to Streptococcus Gallolyticus subspecies Gallolyticus proteins in a large prospective colorectal cancer cohort consortium. In: Cancer Epidemiology Biomarkers and Prevention. 2018 ; Vol. 27, No. 10. pp. 1186-1194.
@article{915f5c76b3b54e9d9d6d92c060034e08,
title = "Antibody responses to Streptococcus Gallolyticus subspecies Gallolyticus proteins in a large prospective colorectal cancer cohort consortium",
abstract = "Background: Antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG) proteins, especially pilus protein Gallo2178, have been consistently associated with colorectal cancer risk. Previous case-control studies and prospective studies with up to 8 years of follow-up, however, were unable to decipher the temporality of antibody responses to SGG in the context of the long-term multistep development of colorectal cancer. In this study, we analyzed a large U.S. colorectal cancer cohort consortium with follow-up beyond 10 years for antibody responses to SGG. Methods: We applied multiplex serology to measure antibody responses to 9 SGG proteins in participants of 10 prospective U.S. cohorts (CLUE, CPSII, HPFS, MEC, NHS, NYUWHS, PHS, PLCO, SCCS, and WHI) including 4,063 incident colorectal cancer cases and 4,063 matched controls. Conditional logistic regression was used to assess whether antibody responses to SGG were associated with colorectal cancer risk, overall and by time between blood draw and diagnosis. Results: Colorectal cancer risk was increased among those with antibody responses to Gallo2178, albeit not statistically significant [OR, 1.23; 95{\%} confidence interval (CI), 0.99- 1.52]. This association was stronger for cases diagnosed <10 years after blood draw (OR, 1.40; 95{\%} CI, 1.09-1.79), but was not found among cases diagnosed ≥10 years after blood draw (OR, 0.79; 95{\%} CI, 0.50-1.24). Conclusions: In a large cohort consortium, we reproduced the association of antibody responses to SGG Gallo2178 with colorectal cancer risk for individuals diagnosed within 10 years after blood draw. Impact: This timing-specific finding suggests that antibody responses to SGG are associated with increased colorectal cancer risk only after tumorigenesis has begun.",
author = "Julia Butt and Blot, {William J.} and Teras, {Lauren R.} and Kala Visvanathan and {Le Marchand}, Lo{\"i}c and Haiman, {Christopher A.} and Yu Chen and Ying Bao and Sesso, {Howard D.} and Sylvia Wassertheil-Smoller and Ho, {Gloria Y.} and Tinker, {Lesley F.} and Peek, {Richard M.} and Potter, {John D.} and Cover, {Timothy L.} and Hendrix, {Laura H.} and Huang, {Li Ching} and Tim Waterboer and Michael Pawlita and Meira Epplein",
year = "2018",
month = "10",
day = "1",
doi = "10.1158/1055-9965.EPI-18-0249",
language = "English (US)",
volume = "27",
pages = "1186--1194",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Antibody responses to Streptococcus Gallolyticus subspecies Gallolyticus proteins in a large prospective colorectal cancer cohort consortium

AU - Butt, Julia

AU - Blot, William J.

AU - Teras, Lauren R.

AU - Visvanathan, Kala

AU - Le Marchand, Loïc

AU - Haiman, Christopher A.

AU - Chen, Yu

AU - Bao, Ying

AU - Sesso, Howard D.

AU - Wassertheil-Smoller, Sylvia

AU - Ho, Gloria Y.

AU - Tinker, Lesley F.

AU - Peek, Richard M.

AU - Potter, John D.

AU - Cover, Timothy L.

AU - Hendrix, Laura H.

AU - Huang, Li Ching

AU - Waterboer, Tim

AU - Pawlita, Michael

AU - Epplein, Meira

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: Antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG) proteins, especially pilus protein Gallo2178, have been consistently associated with colorectal cancer risk. Previous case-control studies and prospective studies with up to 8 years of follow-up, however, were unable to decipher the temporality of antibody responses to SGG in the context of the long-term multistep development of colorectal cancer. In this study, we analyzed a large U.S. colorectal cancer cohort consortium with follow-up beyond 10 years for antibody responses to SGG. Methods: We applied multiplex serology to measure antibody responses to 9 SGG proteins in participants of 10 prospective U.S. cohorts (CLUE, CPSII, HPFS, MEC, NHS, NYUWHS, PHS, PLCO, SCCS, and WHI) including 4,063 incident colorectal cancer cases and 4,063 matched controls. Conditional logistic regression was used to assess whether antibody responses to SGG were associated with colorectal cancer risk, overall and by time between blood draw and diagnosis. Results: Colorectal cancer risk was increased among those with antibody responses to Gallo2178, albeit not statistically significant [OR, 1.23; 95% confidence interval (CI), 0.99- 1.52]. This association was stronger for cases diagnosed <10 years after blood draw (OR, 1.40; 95% CI, 1.09-1.79), but was not found among cases diagnosed ≥10 years after blood draw (OR, 0.79; 95% CI, 0.50-1.24). Conclusions: In a large cohort consortium, we reproduced the association of antibody responses to SGG Gallo2178 with colorectal cancer risk for individuals diagnosed within 10 years after blood draw. Impact: This timing-specific finding suggests that antibody responses to SGG are associated with increased colorectal cancer risk only after tumorigenesis has begun.

AB - Background: Antibody responses to Streptococcus gallolyticus subspecies gallolyticus (SGG) proteins, especially pilus protein Gallo2178, have been consistently associated with colorectal cancer risk. Previous case-control studies and prospective studies with up to 8 years of follow-up, however, were unable to decipher the temporality of antibody responses to SGG in the context of the long-term multistep development of colorectal cancer. In this study, we analyzed a large U.S. colorectal cancer cohort consortium with follow-up beyond 10 years for antibody responses to SGG. Methods: We applied multiplex serology to measure antibody responses to 9 SGG proteins in participants of 10 prospective U.S. cohorts (CLUE, CPSII, HPFS, MEC, NHS, NYUWHS, PHS, PLCO, SCCS, and WHI) including 4,063 incident colorectal cancer cases and 4,063 matched controls. Conditional logistic regression was used to assess whether antibody responses to SGG were associated with colorectal cancer risk, overall and by time between blood draw and diagnosis. Results: Colorectal cancer risk was increased among those with antibody responses to Gallo2178, albeit not statistically significant [OR, 1.23; 95% confidence interval (CI), 0.99- 1.52]. This association was stronger for cases diagnosed <10 years after blood draw (OR, 1.40; 95% CI, 1.09-1.79), but was not found among cases diagnosed ≥10 years after blood draw (OR, 0.79; 95% CI, 0.50-1.24). Conclusions: In a large cohort consortium, we reproduced the association of antibody responses to SGG Gallo2178 with colorectal cancer risk for individuals diagnosed within 10 years after blood draw. Impact: This timing-specific finding suggests that antibody responses to SGG are associated with increased colorectal cancer risk only after tumorigenesis has begun.

UR - http://www.scopus.com/inward/record.url?scp=85054352100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054352100&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-18-0249

DO - 10.1158/1055-9965.EPI-18-0249

M3 - Article

VL - 27

SP - 1186

EP - 1194

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 10

ER -